- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02778438
A Validation Study of the Novel Application of Telehealth in Clinical Drug Development in Subjects With Mild Cognitive Deficits (REINVENT)
REINVENT:A Validation Study of the Novel Application of Telehealth in Clinical Drug Development in Subjects With Mild Cognitive Deficits
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
Mobile platforms have been leveraged in a variety of industries to drive dramatic efficiency gains. The technology enables redesign of key processes allowing for the more efficient use of labor and capital leading to better performance outcomes. Telehealth is the use of electronic information and mobile telecommunications technologies to support long-distance clinical health care, patient and professional health-related education, public health and health administration. Much of the focus for the Institute of Medicine and other government agencies has been the application of telehealth to improve access to healthcare and specialized expertise by extending the reach of scarce resources to underserved populations. These platforms are also routinely deployed as disease management tools. A natural extension of these aims is the use of telehealth in the clinical development process, where both improved efficiency and the ability to be more inclusive of a broader patient population are critical steps in modernizing the clinical trial.
REINVENT is a non-interventional, multi-center, research network-based cross-over study evaluating the potential utility of a telehealth platform in improving the efficiency of clinical trials. The study aims to enroll 30 subjects from between 9 and 11 qualified Radiant Clinical Research primary care physicians (PCP), coordinated through a single main study site. Potential subjects will be screened and randomized (1:1) at Visit 1 into a 2-period crossover design study where 4 standard cognitive outcome measures are administered at Visits 2 (Day 30 ±7) and 3 (Day 90 ±7), either remotely or during an in-person visit. A 60-day interval is required between Visits 2 and 3 to reduce learning effects commonly observed with repeated administration of cognitive assessments.
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
Arizona
-
Gilbert, Arizona, Forenede Stater, 85234
- Clinical Research Advantage, Inc / Neurological Physicians of Arizona, Inc
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Age at screening 50 to 85 years, inclusive, at the time of informed consent.
- Diagnosis of mild cognitive deficits due to AD based on the core clinical diagnostic criteria of the National Institute of Aging and Alzheimer's Association (Albert 2011; McKhann 2011) and reviewed centrally by a main study site Principal Investigator
- Mini Mental State Examination (MMSE) score of 24-27, inclusive at screening
- Subject (or legally authorized representative) is willing and able to provide written informed consent
- Existence of a reliable study partner (i.e., someone who spends at least 2 days a week with the subject) or caregiver who is willing to attend study visits with the subject
- Willing and able to travel to the main study site (via provided transportation) for either Visit 2 or Visit 3
Exclusion Criteria:
- Any medical or neurological condition (other than AD) that might be a contributing cause of the subject's cognitive impairment
- Have had a stroke or transient ischemic attack (TIA) or unexplained loss of consciousness in the past 1 year
- Clinically significant psychiatric illness in past 6 months
- Relevant brain hemorrhage, bleeding disorder and cerebrovascular abnormalities
- Alcohol or substance abuse in past 1 year
- History of unstable angina, myocardial infarction, chronic heart failure (New York Heart Association Class III or IV), or clinically significant conduction abnormalities (e.g., unstable atrial fibrillation) within 1 year prior to Screening.
- Uncontrolled hypertension defined as a systolic blood pressure [SBP]/diastolic blood pressure [DBP] readings > 165/100 mmHg at Screening, or persistent SBP/DBP readings prior to enrollment that in the opinion of the Investigator are indicative of chronic uncontrolled hypertension.
- Any medications that, in the opinion of the Investigator, may contribute to cognitive impairment, or impair the subject's ability to perform cognitive testing.
- Use of allowed chronic medications at doses that have not been stable for at least 4 weeks prior to Screening Visit 1 or use of AD medications (including but not limited to donepezil, rivastigmine, galantamine, tacrine, and memantine) at doses that have not been stable for at least 8 weeks prior to Screening Visit 1.
- Participation in any interventional clinical research study within 30 days prior to screening, or during study conduct
- In the opinion of the Investigator, presence of any other clinical conditions (e.g., life expectancy, co-existing disease) or other characteristics that would likely interfere with completion of the study
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Change in Mini Mental State Examination
Tidsramme: 30 days, 90 days
|
30 days, 90 days
|
Change in Clinical Dementia Rating Sum of Boxes
Tidsramme: 30 days, 90 days
|
30 days, 90 days
|
Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale
Tidsramme: 30 days, 90 days
|
30 days, 90 days
|
Change in Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment version)
Tidsramme: 30 days, 90 days
|
30 days, 90 days
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Jeffrey Shy, MD, Clinical Research Advantage, Inc / Neurological Physicians of Arizona, Inc
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- REI-001
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Mild kognitiv svækkelse
-
Johns Hopkins UniversityNational Institute on Aging (NIA)RekrutteringSøvnforstyrrelser | AMCI - Amnestic Mild Cognitive ImpairmentForenede Stater
-
Dart NeuroScience, LLCAfsluttetAge-Associated Memory Impairment (AAMI)Forenede Stater
-
Charité Neurocure AG FlöelUkendtAfasi | Anomi (ord-finding impairment)Tyskland
-
St. Boniface HospitalPizzey Ingredients; Canadian Agricultural PartnershipAktiv, ikke rekrutterendeHukommelse; Forstyrrelse, MildCanada
-
Saglik Bilimleri UniversitesiAnkara UniversityRekrutteringAmnestisk mild kognitiv svækkelse | Amnestisk mild kognitiv lidelseKalkun
-
XtremeVRI AGAristotle University Of Thessaloniki; Klinik Hirslanden, Zurich; Greek Alzheimer...AfsluttetSund og rask | Mild kognitiv svækkelse, så angivet | Mild demens
-
Aristotle University Of ThessalonikiGreek Alzheimer's Association and Related DisordersAfsluttetSund og rask | Mild kognitiv svækkelse, så angivet | Mild demens
-
Mackay Memorial HospitalBened Biomedical Co., Ltd.RekrutteringMild kognitiv svækkelse (MCI)Taiwan
-
Thomas Jefferson UniversityJohns Hopkins University; University of Pennsylvania; National Institute... og andre samarbejdspartnereAfsluttetMild kognitiv svækkelse (MCI)Forenede Stater
-
Palo Alto Veterans Institute for ResearchU.S. Army Medical Research and Development CommandAfsluttetAmnestisk mild kognitiv svækkelseForenede Stater